Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors.

Autor:	Hughes MS; Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University, Stanford, CA, USA., Aleppo G; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Bally L; Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland., Batista AFMB; Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA., Brown SA; Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.; Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, VA, USA., Faulds ER; College of Nursing, The Ohio State University, Columbus, OH, USA., Gonder-Frederick LA; Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA., Isaacs D; Diabetes Center, Cleveland Clinic, Cleveland, OH, USA., Kahkoska AR; Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Division of Endocrinology and Metabolism, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Center for Aging and Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Ortega J; School of Osteopathic Medicine, Campbell University, Lillington, NC, USA., Polonsky WH; Behavioral Diabetes Institute, San Diego, CA, USA.; University of California San Diego, San Diego, CA, USA., Stumpf MM; Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.; Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Jazyk:	angličtina
Zdroj:	Journal of diabetes science and technology [J Diabetes Sci Technol] 2024 Nov 20, pp. 19322968241296853. Date of Electronic Publication: 2024 Nov 20.
DOI:	10.1177/19322968241296853
Abstrakt:	As diabetes technologies continue to advance, their use is expanding beyond type 1 diabetes to include populations with type 2 diabetes, older adults, pregnant individuals, those with psychiatric conditions, and hospitalized patients. This review examines the psychosocial outcomes of these technologies across these diverse groups, with a focus on treatment satisfaction, quality of life, and self-management behaviors. Despite demonstrated benefits in glycemic outcomes, the adoption and sustained use of these technologies face unique challenges in each population. By highlighting existing research and identifying gaps, this review seeks to emphasize the need for targeted studies and tailored support strategies to understand and optimize psychosocial outcomes and well-being. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MSH has consulted for Dexcom and has received research support through his institution from Insulet, Medtronic, and Tandem. GA has received consultant fees from Dexcom and Insulet and research support through her employer, Northwestern University, from Bayer, Fractyl Health, Insulet, MannKind, and Tandem Diabetes. LB has received product and research support for investigator-initiated studies from Dexcom and Ypsomed, in addition to speaker honoraria from Dexcom and Ypsomed. SAB has received grant support through her institution from Dexcom, Insulet, Roche Diagnostics, Tandem Diabetes Care, and Tolerion and has participated on a DSMB for MannKind. ERF has received grant support from Dexcom and Insulet and has served as a consultant for Dexcom. DI has been a speaker for Abbott Diabetes Care, Dexcom, Eli Lilly, and MannKind Corporation and has consulted for Eli Lilly, Insulet Corporation, Medtronic, and Novo Nordisk. In partnership with the University of Virginia, LAG-F manages fees for licenses for use of the Hypoglycemia Fear Survey (HFS-II) by for-profit organizations, with part of these fees used to support ongoing research and education related to fear of hypoglycemia in people with diabetes and their families. WHP has served as a consultant for Insulet. MMS has received grant support through her institution from Dexcom, Tandem, and Insulet.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu